De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment

被引：1
作者：
Fotiou, Despina [1 ]
Skalioti, Chrysanthi [2 ]
Liapis, George [3 ]
Marinaki, Smaragdi [2 ]
Kastritis, Efstathios [1 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece
[2] Natl & Kapodistrian Univ Athens, Laiko Hosp, Sch Med, Clin Nephrol & Renal Transplantat, Athens, Greece
[3] Natl & Kapodistrian Univ Athens, Laiko Hosp, Sch Med, Dept Pathol, Athens, Greece
来源：
HEMASPHERE | 2021年 / 5卷 / 12期
关键词：
DARATUMUMAB;
D O I：
10.1097/HS9.0000000000000665
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Is drug interference still an issue for pretransfusion testing of patients on anti CD38 and other monoclonal antibody therapies?
    Bevel, Nichole
    Thorpe, Meagan
    Vanniasinkam, Thiru
    VOX SANGUINIS, 2024, 119 (08) : 785 - 791
  • [42] Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab
    Lidicky, Ondrej
    Klener, Pavel
    Machova, Daniela
    Vockova, Petra
    Pokorna, Eva
    Helman, Karel
    Mavis, Cory
    Janouskova, Olga
    Etrych, Tomas
    JOURNAL OF CONTROLLED RELEASE, 2020, 328 (328) : 160 - 170
  • [43] Prognostic value of the "dynamic" R2-ISS in patients with multiple myeloma undergoing anti-CD38 antibody-based triplet therapies
    Kikuchi, Taku
    Oda, Yuki
    Kondo, Ukyo
    Tsukada, Nobuhiro
    Kunisada, Kodai
    Matsumoto, Chiaki
    Nomura-Yogo, Moe
    Sato, Kota
    Takei, Tomomi
    Ogura, Mizuki
    Abe, Yu
    Suzuki, Kenshi
    Hosoya, Osamu
    Ishida, Tadao
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (05)
  • [44] Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
    de Zafra, Christina L. Zuch
    Fajardo, Flordeliza
    Zhong, Wendy
    Bernett, Matthew J.
    Muchhal, Umesh S.
    Moore, Gregory L.
    Stevens, Jennitte
    Case, Ryan
    Pearson, Joshua T.
    Liu, Siyuan
    McElroy, Patricia L.
    Canon, Jude
    Desjarlais, John R.
    Coxon, Angela
    Balazs, Mercedesz
    Nolan-Stevaux, Olivier
    CLINICAL CANCER RESEARCH, 2019, 25 (13) : 3921 - 3933
  • [45] Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus-associated refractory cerebral vasculitis induces immune tolerance
    Yalcin Mutlu, Melek
    Wacker, Jochen
    Tascilar, Koray
    Taubmann, Jule
    Manger, Bernhard
    Kronke, Gerhard
    Schett, Georg
    Simon, David
    RHEUMATOLOGY, 2023, 62 (02) : E21 - E23
  • [46] CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells
    Wang, Hongjie
    Koob, Theo
    Fromm, Jonathan R.
    Gopal, Ajay
    Carter, Darrick
    Lieber, Andre
    CANCER BIOLOGY & THERAPY, 2024, 25 (01)
  • [47] Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of de novo donor-specific antibodies
    Zhu, Lan
    Guo, Zhiliang
    Zhao, Daqiang
    Sa, Rula
    Zhao, Guangyuan
    Guo, Hui
    Chen, Gang
    FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [48] Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials
    Ye, Lu
    Zhou, Fei
    Cheng, Dongdong
    Xie, Ming
    Yan, Xiaoli
    Xue, Yuyu
    Yang, Qian
    Jia, Rong
    Zhong, Lili
    Yang, Li
    Zou, Liqun
    Huang, Na
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [49] Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity
    Yu, Tao
    Qiao, Chunxia
    Lv, Ming
    Tang, Luqun
    BMC BIOTECHNOLOGY, 2019, 19 (1)
  • [50] Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity
    Tao Yu
    Chunxia Qiao
    Ming Lv
    Luqun Tang
    BMC Biotechnology, 19
12345